dm+d

Unassigned

New Medicines

Alzheimer's disease

Information

New molecular entity
Biohaven Pharmaceuticals
Biohaven Pharmaceuticals

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Third generation, tripeptide, glutamate modulator - reduces presynaptic glutamate release altering GABAergic neurotransmission and BDNF.[1]
AD is the most common form of dementia. It is estimated to affect 520,000 people in the UK. [2]
Alzheimer's disease
Oral